Invention Grant
- Patent Title: Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof
-
Application No.: US16625025Application Date: 2018-06-25
-
Publication No.: US11718611B2Publication Date: 2023-08-08
- Inventor: Yihan Wang , Zhiqiang Liu
- Applicant: Shenzhen TargetRx, Inc.
- Applicant Address: CN Guangdong
- Assignee: Shenzhen TargetRx, Inc.
- Current Assignee: Shenzhen TargetRx, Inc.
- Current Assignee Address: CN Guangdong
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: CN 1710493544.X 2017.06.26
- International Application: PCT/CN2018/092588 2018.06.25
- International Announcement: WO2019/001383A 2019.01.03
- Date entered country: 2019-12-20
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/496 ; A61P35/00 ; A61P35/02
Abstract:
An N-benzenesulfonylbenzamide compound represented by the formula (I), or a crystal form, a prodrug, pharmaceutically acceptable salts, a stereoisomer, a solvate or a hydrate thereof, a pharmaceutical composition containing same, and a use thereof as a Bcl-2 protein inhibitor for preparing a medicament for treatment of leukemia or a cancer.
Public/Granted literature
- US20200216442A1 BENZENESULFONYLBENAZAMIDE COMPOUND FOR INHIBITING BCL-2 PROTEIN AND COMPOSITION AND USE THEREOF Public/Granted day:2020-07-09
Information query
